Claims
- 1. A device for implanting autologous vascular smooth muscle cells transduced with a gene of interest in a patient, comprising:
a tubular elongate member having a wall, which wall has an interior surface, an exterior surface, and pores therein; the autologous smooth muscle cells transduced with the gene of interest immobilized within the pores and upon the interior surface of the wall to form a tubular smooth muscle cell complex having an interior surface; and autologous vascular endothelial cells adherent to the interior surface of the tubular smooth muscle cell complex.
- 2. A device as in claim 1, wherein the tubular elongate member is comprised of a porous synthetic material.
- 3. A device as in claim 2, wherein the porous synthetic material is polytetrafluoroethylene (PTFE), dacron or nylon.
- 4. A device as in claim 3, wherein the tubular elongate member is a vascular graft.
- 5. A device as in claim 1, wherein the autologous vascular smooth muscle cells are transduced with a gene encoding erythropoietin.
- 6. A device as in claim 1, wherein the vascular smooth muscle cells are transduced with a gene encoding granulocyte colony stimulating factor or granulocyte macrophage colony stimulating factor.
- 7. A device as in claim 1, wherein the vascular smooth muscle cells are transduced with a gene encoding Factor IX.
- 8. A device as in claim 1, wherein the transduced cells constitutively express an anticoagulant.
- 9. A device as in claim 1, wherein the transduced autologous vascular smooth muscle cells are immobilized to the tubular elongate member with a polymer.
- 10. A device as in claim 9, wherein the polymer is collagen or fibronectin.
- 11. A method for introducing a gene of interest to a patient comprising:
engrafting a device as in claim 1 into the patient's vascular system, wherein the transduced vascular smooth muscle cells contain the gene operably linked to a promoter for expression.
- 12. A method as in claim 11, wherein the gene encodes erythropoietin, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, or Factor IX.
- 13. A method as in claim 11, wherein the device is engrafted into the patient's arterial system.
- 14. A method for treating anemia in a patient, comprising engrafting a device as in claim 1 into the patient's vascular system, wherein the transduced autologous smooth muscle cells express erythropoietin.
- 15. The method of claim 14, wherein the device is engrafted into the patient's arterial system.
- 16. A method for treating an occlusion of a blood vessel in a patient, comprising engrafting a device as in claim 1 into the occluded blood vessel bypassing the occlusion, wherein the transduced cells constitutively express an anticoagulant protein.
- 17. A method as in claim 16, wherein the anticoagulant is a plasminogen activator or antithrombin-III.
- 18. A method as in claim 17, wherein the plasminogen activator is alteplase or urokinase.
- 19. A method for treating or preventing diabetes in a patient, comprising engrafting a device as in claim 1 into the patient, wherein the transduced cells constitutively express an insulin or proinsulin polypeptide.
- 20. A method for treating or preventing a disease in a mammal, comprising:
removing vascular endothelial cells and vascular smooth muscle cells from the mammal; transducing the smooth muscle cells with a gene which encodes a product for treating or preventing the disease, operably linked to a promoter; immobilizing on a tubular elongate porous vascular graft device the transduced smooth muscle cells within the pores and interior surface of the graft; coating the interior of the graft device having immobilized thereon the transduced smooth muscle cells with the endothelial cells; and engrafting the device having the immobilized transduced smooth muscle cells and endothelial cells into the vasculature of the mammal to treat or prevent the disease.
- 21. The method of claim 20, further comprising the step of cultivating the vascular smooth muscle cells obtained from the mammal in a medium containing autologous serum prior to immobilizing the cells on the vascular graft.
- 22. The method of claim 21, further comprising the step of cultivating the vascular endothelial cells obtained in a medium containing autologous serum prior to coating the vascular graft.
GOVERNMENT SUPPORT
[0001] This invention was made with U.S. government support under grants from the National Institutes of Health. The U.S. government may have certain rights in this invention.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08217324 |
Mar 1994 |
US |
Child |
10765306 |
Jan 2004 |
US |